Literature DB >> 21854101

Long-term follow-up after radical cystectomy with emphasis on complications and reoperations: a Swedish population-based survey.

Fredrik Liedberg1, Erik Holmberg, Sten Holmäng, Börje Ljungberg, Per-Uno Malmström, Wiking Månsson, Leyla Nunez, Catrin Wessman, Hans Wijkström, Staffan Jahnson.   

Abstract

OBJECTIVE: To evaluate outcome after radical cystectomy for primary bladder cancer in a large population-based material.
MATERIAL AND METHODS: Between 1997 and 2002 all patients treated with radical cystectomy within 3 months after diagnosis of primary bladder cancer without distant metastasis were retrieved through the Swedish Bladder Cancer Registry. A follow-up questionnaire was distributed to all units where the primary registration of patients was performed. Follow-up data on recurrence date were retrieved from the patient charts and causes of death were obtained from the Swedish Cause of Death Registry until 2003.
RESULTS: During the study period radical cystectomy was performed in 39 units in Sweden, of which only five units were considered high-volume hospitals performing 10 or more procedures annually. Mean blood loss was 2300 ml (median 2000 ml) and the 90-day mortality rate was 5.7%. Blood loss was higher in high-volume units than in hospitals with lower hospital volumes, but the 90-day mortality rates were similar. During a median follow-up of 3.5 years, 24% of the patients were submitted to a reoperation. Reoperation rates were significantly higher in patients who received a continent urinary diversion (29%) compared with an ileal conduit (22%, p < 0.015).
CONCLUSIONS: Radical cystectomy was associated with a reoperation rate of 24% in Sweden during the study period. The reoperation rates were higher in patients receiving a continent cutaneous diversion or bladder substitution. Blood loss was higher in high-volume units; otherwise, surgical volume did not affect mortality rates, cancer-specific survival or reoperation rates.

Entities:  

Mesh:

Year:  2011        PMID: 21854101     DOI: 10.3109/00365599.2011.609835

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  6 in total

1.  Radiotherapy in muscle-invasive bladder cancer: the latest research progress and clinical application.

Authors:  Shuo Zhang; Yong-Hua Yu; Yong Zhang; Wei Qu; Jia Li
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

2.  Risk of in-hospital complications after radical cystectomy for urinary bladder carcinoma: population-based follow-up study of 7608 patients.

Authors:  Mieke van Hemelrijck; Andreas Thorstenson; Philip Smith; Jan Adolfsson; Olof Akre
Journal:  BJU Int       Date:  2013-07-26       Impact factor: 5.588

3.  Survival after radiotherapy versus radical cystectomy for primary muscle-invasive bladder cancer: A Swedish nationwide population-based cohort study.

Authors:  Christel Häggström; Hans Garmo; Xavier de Luna; Mieke Van Hemelrijck; Karin Söderkvist; Firas Aljabery; Viveka Ströck; Abolfazl Hosseini; Truls Gårdmark; Per-Uno Malmström; Staffan Jahnson; Fredrik Liedberg; Lars Holmberg
Journal:  Cancer Med       Date:  2019-04-01       Impact factor: 4.452

4.  Cumulative incidence of midline incisional hernia and its surgical treatment after radical cystectomy and urinary diversion for bladder cancer: A nation-wide population-based study.

Authors:  Fredrik Liedberg; Oskar Hagberg; Firas Aljabery; Truls Gårdmark; Staffan Jahnson; Tomas Jerlström; Agneta Montgomery; Amir Sherif; Viveka Ströck; Christel Häggström; Lars Holmberg
Journal:  PLoS One       Date:  2021-02-04       Impact factor: 3.240

5.  Short-term morbidity and mortality following radical cystectomy: a systematic review.

Authors:  Sophia Liff Maibom; Ulla Nordström Joensen; Alicia Martin Poulsen; Henrik Kehlet; Klaus Brasso; Martin Andreas Røder
Journal:  BMJ Open       Date:  2021-04-14       Impact factor: 2.692

6.  Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe).

Authors:  Christel Häggström; Fredrik Liedberg; Oskar Hagberg; Firas Aljabery; Viveka Ströck; Abolfazl Hosseini; Truls Gårdmark; Amir Sherif; Per-Uno Malmström; Hans Garmo; Staffan Jahnson; Lars Holmberg
Journal:  BMJ Open       Date:  2017-09-27       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.